Neurocrine Biosciences v. Lupin — 18-Patent Valbenazine Dispute Dismissed Without Prejudice
Neurocrine Biosciences filed suit in the District of Delaware against Lupin Limited and affiliated entities, asserting 18 patents covering valbenazine (VMAT2 inhibitor) formulations, methods of administration, and related compositions. The parties jointly stipulated to dismiss all claims without prejudice after 773 days of litigation, with the court retaining jurisdiction to enforce the resolution.
Eighteen-Patent VMAT2 Battle Ends in No-Cost Stipulated Dismissal
On 1 October 2021, Neurocrine Biosciences, Inc. filed an infringement action in the U.S. District Court for the District of Delaware against Lupin Limited, Lupin Atlantis Holdings S.A., Lupin Pharmaceuticals, Inc., and Lupin, Inc. The complaint asserted 18 U.S. patents covering valbenazine active pharmaceutical ingredient chemistry, salt forms, polymorphs, high-dosage formulations, and methods of administering the VMAT2 inhibitor — the active ingredient in Ingrezza, Neurocrine's approved treatment for tardive dyskinesia. The case was assigned to Judge Maryellen Noreika.
The recorded basis of termination is 'Dismissed without Prejudice.' The docket order states that, pursuant to Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), the parties stipulated to dismiss all claims, counterclaims, and affirmative defenses without prejudice and without costs, disbursements, or attorneys' fees to any party. The order further provides that the District of Delaware retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions. The specific terms of any underlying resolution are not disclosed in the available record.
The 773-day duration suggests the parties litigated through at least some substantive phase before reaching their agreement. The express retention of jurisdiction by the District of Delaware is notable — it is consistent with an underlying agreement that the court may need to police, though the content of any such agreement is not in the public record. What remains unknown is whether any commercial arrangement between Neurocrine and Lupin accompanies this dismissal, and whether the without-prejudice posture signals an intent to re-file if any future dispute arises.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 773 days
773 days from filing to dismissal — a substantial ANDA-era litigation timeline before trial
US10851104B2 and 17 further patents — valbenazine VMAT2 inhibitor portfolio
Any pharmaceutical company — generic, branded, or biosimilar-adjacent — developing a VMAT2 inhibitor product or a valbenazine-containing formulation should treat this 18-patent portfolio as a live risk. The without-prejudice dismissal means no patent has been adjudicated invalid or not infringed. Formulation scientists, regulatory teams preparing ANDA submissions, and product managers planning CNS pipeline entries in the tardive dyskinesia or Tourette space are all directly in scope.
Official order — verbatim text
The stipulation invokes FRCP 41(a)(1)(A)(ii) and 41(c), effecting a joint dismissal of all claims, counterclaims, and affirmative defenses without prejudice and without costs. No court has ruled on the validity or infringement of any of the 18 asserted patents. The express retention of jurisdiction by the District of Delaware distinguishes this filing from a bare voluntary dismissal and is consistent with the existence of an underlying resolution between the parties, the terms of which are not in the public record.
Dismissed without prejudice: what the stipulated dismissal means for both parties
Rule 41 stipulated dismissal — no merits adjudication
Under FRCP 41(a)(1)(A)(ii), parties may jointly stipulate to dismiss without a court order. Here, all 18 patent claims, counterclaims, and affirmative defenses were dismissed without prejudice, meaning no court has ruled on validity or infringement. The court expressly retained jurisdiction to enforce any resolution between the parties — an unusual feature of a pure 41(a) dismissal that suggests the parties entered into a separate agreement.
No merits rulingNeurocrine preserves all 18 patents — re-filing remains open
A dismissal without prejudice leaves all 18 asserted patents legally intact and enforceable. Neurocrine retains the right to re-assert any of them against Lupin if a new triggering event arises — for example, a future ANDA filing or product launch. No admission of invalidity or non-infringement was made on the public record. The retained-jurisdiction clause also gives Neurocrine a direct enforcement path if the underlying resolution is breached.
Patents preservedLupin avoids an adverse ruling but faces unresolved patent exposure
Lupin and its affiliates exit this action without a finding of infringement and without incurring court-awarded costs. However, the without-prejudice posture means none of the 18 patents were declared invalid or not infringed. Any future commercial steps by Lupin in the valbenazine space could re-trigger litigation under one or more of Neurocrine's asserted patents. The specific terms of any resolution between the parties are not disclosed in the available record.
No invalidity findingVMAT2 generic entry timeline remains uncertain
With 18 patents dismissed without prejudice and no validity or infringement determination, the competitive landscape for generic valbenazine entry remains unresolved in the public record. Other generic filers in the VMAT2 space will need to account for Neurocrine's broad portfolio — covering chemistry, salt forms, polymorphs, dosage forms, and methods — when assessing freedom to operate. The court's retained jurisdiction adds a layer of complexity for third-party assessment of this settlement posture.
Generic entry uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Neurocrine Biosciences, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Lupin Limited | Individual | /Search in Eureka ↗ |
| Co-Defendant | Lupin Atlantis Holdings, S.A. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Lupin, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Erin M. Sommers | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James B. Monroe | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeanette M. Roorda | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren J. Dowty | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | James Michael Lennon | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jillian M. Schurr | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant counsel | Jitendra M. Malik | Attorney | Counsel for Lupin LimitedSearch in Eureka ↗ |
| Defendant law firm | Devlin Law Firm LLC | Law Firm | Representing Lupin LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the VMAT2 inhibitor and CNS small-molecule space
Forward-looking patent and innovation intelligence derived from Neurocrine's 18-patent valbenazine portfolio and the broader VMAT2 competitive landscape.
Neurocrine's VMAT2 filing ladder spans compound to method claims
Neurocrine's 18 asserted patents reflect a multi-layer lifecycle strategy: core compound chemistry filed as early as 2006, followed by salt/polymorph, formulation, and method-of-use filings through 2020. Monitoring continuation and divisional activity in these application families can surface new blocking claims before they issue — a critical signal for any company building a VMAT2 pipeline.
Portfolio filing strategyVMAT2 inhibitor patent activity is accelerating beyond tetrabenazine
The VMAT2 inhibitor class — which includes valbenazine and deutetrabenazine alongside older tetrabenazine — is attracting increased patent filing activity in formulation, dosing regimen, and combination therapy claims. Companies monitoring this space should track filing trends across applicants to identify white-space opportunities in dosage forms, patient subpopulations, and new indications such as Tourette syndrome or Huntington's disease chorea.
VMAT2 filing trendsLupin's ANDA strategy in CNS exposes its broader small-molecule approach
Lupin's engagement in this 18-patent dispute, through multiple affiliated entities, signals active interest in the VMAT2 generics market. Examining Lupin's own patent filings and ANDA history in CNS small molecules can reveal which formulation technologies and process patents the company is developing to support future generic or branded CNS entries — useful intelligence for competitors and licensing teams alike.
Lupin CNS IP activityGaps in VMAT2 delivery formats and combination regimens remain open
Neurocrine's portfolio concentrates on oral solid dosage forms, salt forms, and standard administration methods. Adjacent innovation opportunities — such as modified-release formulations, transdermal delivery, or VMAT2 inhibitor combination therapies for comorbid conditions — may fall outside the current claim landscape. A targeted white-space analysis of VMAT2-adjacent filing activity could reveal defensible R&D entry points for differentiated products.
VMAT2 white spaceSimilar VMAT2 and CNS ANDA patent disputes in the District of Delaware
Explore comparable Hatch-Waxman infringement actions involving CNS small-molecule formulation patents litigated in the District of Delaware.
What this case signals for the VMAT2 and CNS small-molecule IP landscape
An 18-patent ANDA dispute dismissed without prejudice leaves significant enforceability and FTO questions open for any party targeting the valbenazine market.
Broad portfolio depth deters generics even without a trial verdict
Neurocrine's assertion of 18 patents across chemistry, formulation, and method claims creates layered exposure for any generic entrant. A dismissal without prejudice does nothing to thin the portfolio — each patent remains independently enforceable, meaning a challenger must defeat every claim to achieve clear market entry.
Retained court jurisdiction is an atypical signal worth monitoring
The stipulation's express retention of jurisdiction by the District of Delaware suggests an underlying agreement is in place. IP professionals tracking this space should monitor the docket for any enforcement motions or subsequent filings that might reveal the terms of the parties' resolution.
Neurocrine v Lupin — key questions answered
The case was dismissed without prejudice. All claims, counterclaims, and affirmative defenses were dismissed by joint stipulation under FRCP 41(a)(1)(A)(ii) and 41(c), with no costs, disbursements, or attorneys' fees awarded to any party. The District of Delaware retained jurisdiction to enforce any resolution between the parties. No court ruled on the validity or infringement of any of the 18 asserted patents.
Neurocrine asserted 18 U.S. patents, including US10851104B2, US11026931B2, US10906902B2, US10065952B2, US11040029B2, US10919892B2, US8039627B2, US8357697B2, US10874648B2, US10844058B2, US10857137B2, US10912771B1, US11026939B2, US10952997B2, US10940141B1, US10906903B2, US10993941B2, and US10857148B2, covering valbenazine formulations, VMAT2 inhibitor methods, compound chemistry, and salt and polymorph forms.
A dismissal without prejudice means the case was terminated without any ruling on the merits — no court determined whether the asserted patents are valid or infringed. Neurocrine retains the right to re-assert any of the 18 patents against Lupin if a future triggering event arises, such as a product launch or new ANDA amendment. Lupin received no judicial declaration of non-infringement or invalidity.
The stipulation expressly provides that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions. This clause is atypical for a bare voluntary dismissal and suggests the parties entered into an underlying agreement that the court may need to enforce. The specific terms of that agreement are not disclosed in the available public record.
The products at issue included high-dosage valbenazine formulations and compositions (including methods and kits), methods for administration of VMAT2 inhibitors, substituted 3-isobutyl-9,10-dimethoxy hexahydro-pyrido-isoquinolinol compounds and related methods, and valbenazine salts and polymorphs. Valbenazine is the active ingredient in Neurocrine's Ingrezza, approved for tardive dyskinesia.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.